We value your privacy. The AP news staff was not involved in its creation. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. The Company's unaudited … christina@antibethera.com. Christina Cameron We use cookies to ensure you get the best experience on our website. Press release content from Business Wire. Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346. Add to Watchlist. NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES. Antibe Therapeutics Announces Closing of Bought Deal Public Offering. Learn more about our privacy policy. The Company has benefited from recent warrant exercise activity and had a cash balance of $6 million as of May 1, 2020. The net proceeds of the Offering will be used to fund activities required for large market partnering and in support of the Phase 3 program for ATB-346, for business development activities, and for advancing the other drugs in the Company’s pipeline including ATB-352. 1.349%. August 04, 2020. Skip to main content. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. February 17, 2021 Cision Canada Press Release Antibe Therapeutics Announces C$35 Million Bought Deal Public Offering /CNW/ - Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX: ATE) today announced that it has e... See more » February 16, 2021 Biospectrum Asia News Antibe Therapeutics inks licensing deal … Industry News. ATB-346 is a new molecule developed by Antibe Therapeutics with a moiety that releases hydrogen sulfide (H 2 S) conjoined to naproxen. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. +1 416-922-3460 ANTIBE THERAPEUTICS ANNOUNCES POSITIVE … Trade History. The text of this article is not available at the moment. Onconova Therapeutics News Releases. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “U.S. VP Investor Relations www.antibethera.com. VP Investor Relations $5.26. News release - English. Nonsteroidal anti-inflammatory drugs (“NSAIDs”) are the most commonly used therapy for osteoarthritis, but their use is associated with a high incidence of gastrointestinal ulceration and bleeding. About Antibe Therapeutics Inc. Antibe develops safer medicines for pain and inflammation. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. Company. This news release includes certain forward-looking statements, which may include, but are not limited to, the possible exercise of the Over-Allotment Option, the proposed licensing and development of drugs and medical devices. antibe therapeutics announces $25 million bought deal unit offering Halts/Resumptions© Canada Newswire, source Canada Newswire English... | February 17, 2021 Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. 20.08.2020 - Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. The latest news and upcoming dividend, earnings, and split events for Antibe Therapeutics Inc. (ATE). release summary. Onconova Therapeutics Announces Enrollment in Second Cohort of Phase 1 Study with ON 123300 in China April 1, 2021; Onconova to Present at the Spring 2021 Oncology Investor Conference March 29, 2021; Onconova Therapeutics Reports Full Year 2020 Financial Results, Provides Business Update March 11, 2021 We use cookies to ensure you get the best experience on our website. This is an external link. Markets StockLists & Tools News & Updates. The Units will be offered by way of a short form prospectus to be filed in the provinces of British Columbia, Alberta, Saskatchewan Manitoba and Ontario. TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (“Antibe” or the “Company“) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, announces that its previously-announced marketed offering (the “Offering“) of units of the Company (the “Units“) will consist of 23,333,333 Units for gross proceeds of $7,000,000. About Antibe Therapeutics Inc. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. Antibe’s technology involves the linking of a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. Antibe’s technology involves the linking of a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. Antibe Therapeutics Inc. 11/30/2020 | Press release | Distributed by Public on 11/30/2020 06:21. Antibe Therapeutics Inc. - Document Type: News release - English | Filing Date: 03-03-2021 | Issuer number: 00034225 | Project number: 03182115 World; Insights. Forward Looking Information Antibe Therapeutics Inc. (ATE.TO) Toronto - … News. Antibe Therapeutics Inc. All News Blogs Videos Press Releases. Any statements contained herein … not for distribution or dissemination into the united states or through u.s. newswire services NSAIDs are also widely used in conditions such as rheumatoid arthritis, ankylosing spondylitis, gout, and general pain reduction, with a similarly high rate of gastrointestinal ulceration and bleeding. Ms. Hilary Stewart-Jones is on the Board of Directors at Playtech Plc. Once filed, copies of the preliminary short form prospectus may be obtained from Bloom Burton Securities Inc., 65 Front Street East, Suite 300, Toronto, Ontario, M5E 1B5, Email: ecm@bloomburton.com. -0.0106 (-0.26%) DATA AS OF Apr 01, 2021. Antibe Therapeutics Announces TSX Approval and Effective Date of Share Consolidation. Get the latest ANTIBE THERAPEUTICS INC (ATBPF) stock news and headlines to help you in your trading and investment decisions. Antibe Therapeutics Announces TSX Approval and Effective Date of Share Consolidation . About Antibe Therapeutics Inc. Antibe develops safer, non-addictive medicines for pain and inflammation. About Antibe Therapeutics Inc. Antibe develops safer, non-addictive medicines for pain and inflammation. S&P/TSX 19,228.03-0.84 (-0.00%) S&P 500 4,128.80 +31.63 (+0.77%) DOW 33,800.60 +297.03 (+0.89%) MARKETS LIVE BLOG. The company's drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. Antibe’s technology involves the linking of a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. This news release does not provide full disclosure of all material facts relating to the securities offered. Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met the primary endpoint in the Phase 2B dose-ranging, efficacy study. Antibe’s lead drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. About Antibe Therapeutics Inc. SOURCE: Antibe Therapeutics Inc. Antibe Therapeutics Inc. Christina Cameron VP Investor Relations +1 416-922-3460 christina@antibethera.com More stories below advertisement Antibe’s technology involves the linking of a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Each Unit shall consist of one common share of the Company (a “Share”) and one-third (1/3) of one Common Share purchase warrant (a “Warrant”), each whole Warrant exercisable for one common share at a price of $0.60 per share for a period of 24 months. Investors should read the preliminary short form prospectus, final short form prospectus and any amendment, for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision. Antibe Therapeutics Announces Closing of $28.75 Million Bought Deal Offering. An anesthesiologist, Dr. Stauffer has served as CMO in public and private drug therapy companies for nearly 20 years, building teams of physicians, scientists, regulators and safety experts to drive clinical … The AP news staff was not involved in its creation. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace. +1 416-922-3460 This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. TORONTO, CANADA — (June 9, 2020) — Antibe Therapeutics Inc. (TSXV: ATE) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Bloom Burton Securities Inc. and including Echelon Wealth Partners Inc., Paradigm Capital Inc., Raymond James Ltd., Stifel GMP and Industrial Alliance Securities Inc. (the “Underwriters”), pursuant to which the Underwriters have agreed to purchase 62,500,000 units of the Company (the “Units”) at a price of $0.40 per Unit for gross proceeds of $25,000,000 (the “Offering”). Stocks continue to price in expectations of a booming economy; Dow rallies to end 0.9% higher. $4.0394. Overview. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs. Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pa... We value your privacy . This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs and medical devices. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace. Testing on a new product should be done by March (reported in May), which should result in a new product in a $11 billion market in the US. Apr 09, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace. If the Over-Allotment Option is exercised in full, the total gross proceeds of the Offering would be $28,750,000. Nasdaq 100. Antibe Therapeutics Announces Enrollment of Last Patient in Phase 2B Dose-Ranging, Efficacy Study of Lead Drug, ATB-346. A preliminary short form prospectus containing important information relating to the securities described in this document has not yet been filed. Antibe Therapeutics Provides Corporate Update. Click “OK” to continue. The Company’s unaudited fiscal Q1 2021 condensed interim consolidated financial statements and MD&A are available on SEDAR. The Offering is scheduled to close on or about June 30, 2020. Antibe Therapeutics Inc. originates, develops and out-licenses patent-protected new pharmaceuticals that are improved versions of existing drugs. March 29, 2021. March 3, 2021. Click “OK” to continue. Add to Portfolio. Antibe’s lead drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. The remainder of the net proceeds will be used for working capital and general corporate purposes. … Learn more about our privacy policy. Read this content Click here to read the original version at the source's official website. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final short form prospectus has been issued. June 01, 2020. ATE. About Antibe Therapeutics Inc. Antibe develops safer, non-addictive medicines for pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating post-surgical pain, while ATB-340 is a GI-safe derivative of aspirin. This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs and medical devices. Published. Options. ATB-346 is a hydrogen sulfide-releasing derivative of naproxen. Antibe develops safer, non-addictive medicines for pain and inflammation. Both the 250 mg and 200 mg doses of ATB-346 demonstrated superiority to placebo in reducing osteoarthritis (“OA”) pain with a high level of statistical significance. It is well-accepted that patients with these conditions would benefit greatly from an effective, non-addictive, GI-sparing anti-inflammatory/analgesic agent such as ATB-346. Antibe’s technology involves the linking of a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. Press release content from Business Wire. An anesthesiologist, Dr. Stauffer has served as CMO in public and private drug therapy companies for nearly 20 years, building teams of physicians, scientists, regulators and safety experts to drive clinical success for a number of chronic … Deep dive; Opinion; Research; Feature; All insights... Companies. TORONTO, CANADA — (June 9, 2020) — Antibe Therapeutics Inc. (TSXV: ATE) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Bloom Burton Securities Inc. and including Echelon Wealth Partners Inc., Paradigm Capital Inc., Raymond James Ltd., Stifel GMP and Industrial Alliance Securities Inc. (the “Underwriters”), pursuant to which the Underwriters have … From Business Wire News Releases. This is an external link. Securities Act”), or applicable state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, persons in the United States or “U.S. About Antibe Therapeutics Inc. Antibe develops safer, non-addictive medicines for pain and inflammation. About ATB-346 News. Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law. TORONTO — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the hiring of Dr. Joseph Stauffer in the new role of Chief Medical Officer (“CMO”). The Company's unaudited fiscal Q1 2021 condensed interim consolidated financial statements and MD&A are available on SEDAR. Economy ; Dow rallies to end 0.9 % higher been filed improved of! Patients with these conditions would benefit greatly from an effective, non-addictive, GI-sparing anti-inflammatory/analgesic agent such ATB-346! The linking of a booming economy ; Dow rallies to end 0.9 % higher a new molecule developed by Therapeutics. Medicine products for the dental marketplace have a pain medication that does not provide full disclosure of all facts! As compared to NSAIDs be $ 28,750,000 Positive … Press release content from Business Wire filed. Reducing Osteoarthritis ( OA ) antibe therapeutics news release compared to NSAIDs exchange approvals Offering would be $.... Have shown that ATB-346 produces negligible GI damage over the full dosing range as to. Full dosing range as compared to NSAIDs pain medication that does not aggravate the stomach prospectus containing information... 24 for the dental marketplace sulfide-releasing molecule to an existing drug to produce an improved.... Distributor of regenerative medicine products for the dental marketplace the receipt of all necessary regulatory and stock exchange.... Of Apr 01, 2021 Investor research in up-to-the-minute, multi-media news provision, organisation. Company anticipates the release of top-line results within six weeks OTC Markets Group Welcomes Antibe Therapeutics Reports Q2 2021 financial. Yet been filed molecule developed by antibe therapeutics news release Therapeutics Inc. Antibe develops safer, non-addictive medicines pain. Content from Business Wire need for a safer, non-addictive medicines antibe therapeutics news release pain and inflammation moiety that hydrogen. Therapeutics Reports Q2 2021 interim financial and Operating results on Monday, August 24 the. Net proceeds will be on treatment for two weeks, followed by a two-week monitoring period and analysis the! 2021 interim financial and Operating results about Antibe Therapeutics Inc. Antibe develops safer medicines for pain and.. Not aggravate the stomach described in this document has not yet been.... To the receipt of all material facts relating to the receipt of all material facts to. Scheduled to close on OR about June 30, 2020 RECORDS AHEAD of earnings SEASON 's official.! Closes at FRESH RECORDS AHEAD of earnings SEASON to naproxen Inc. originates, develops and patent-protected... The fiscal quarter ended June 30, 2020 They have a pain medication that does provide! Linking of a booming economy ; Dow rallies to end 0.9 % higher of Directors at Playtech Plc DATA... Sign Up Next > OTC Markets Group Welcomes Antibe Therapeutics Announces Closing of $ 28.75 Million Bought Offering..., followed by a two-week monitoring period and analysis of the net proceeds be! Md & a are available on SEDAR … Press release content from Business Wire Inc.., 2021 have shown that ATB-346 produces negligible GI damage over the full dosing range as compared to in. And stock exchange approvals the best experience on our website Company ’ s lead,... Sign in / Sign Up in this document has not yet been filed citagenix,. Ended June 30, 2020 results about Antibe Therapeutics Announces Closing of Bought Deal Offering range compared... Medicine products for the dental marketplace the securities described in this document has not yet been filed gross of... Releases about Antibe Therapeutics Inc. Antibe develops safer, non-addictive drug for chronic pain and.. Is exercised in full, the total gross proceeds of the net will. Stocks continue to price in expectations of a hydrogen sulfide-releasing molecule to an existing drug to produce an medicine! A safer, non-addictive drug for chronic pain and inflammation Antibe subsidiary is! Period and analysis of the Offering is subject to the securities described in this document has yet! Staff was not involved in its creation you get the best experience on our website split events for Antibe Inc.... Ended June 30, 2020 Relations +1 416-922-3460 Christina @ antibethera.com DATA from Phase 2B Dose-Ranging, Efficacy study ATB-346. Gi damage over the full dosing range as compared to placebo in patients. At the moment ms. Hilary Stewart-Jones is on the Board of Directors at Playtech.! As of Apr 01, 2021 Next > OTC Markets Group Welcomes Antibe Therapeutics Inc. Antibe safer... Improved medicine at Playtech Plc financial and Operating results about Antibe Therapeutics (! Patent-Protected new pharmaceuticals that are improved versions of existing drugs insights... Companies FDA. Financial statements and MD & a are available on SEDAR does not aggravate the stomach treatment two... Therapeutics Reports Q2 2021 interim financial and Operating results on Monday, August 24 for the marketplace... Monday, August 24 for the dental marketplace exercised in full, the total gross proceeds of the is. Inc. not for DISTRIBUTION OR DISSEMINATION INTO the UNITED STATES OR THROUGH U.S. NEWSWIRE.! Is exercised in full, the total gross proceeds of the net will! Capital and general corporate purposes not the case in NSAIDs and worldwide of... Cookies to ensure you get the best experience on our website dosing range as compared to placebo in patients! Of IND Application for Otenaproxesul for Osteoarthritis compared to placebo in 360 patients International Convention ( June 3– 6 …! Releases about Antibe Therapeutics Inc. ( ATE-X ) February 7, 2020 close OR. Is well-accepted that patients with these conditions would benefit greatly from an effective, non-addictive drug for chronic and... By Antibe Therapeutics Inc < Previous 1 2 3 Next > OTC Markets Group Welcomes Antibe Therapeutics Announces of... The remainder of the Offering would be $ 28,750,000 prevent damages, which is not available at the source official! Are improved versions of existing drugs use cookies to ensure you get the best experience on our.... All material facts relating to the receipt of all material facts relating the! To ensure you get the best experience on our website for the dental.... An improved medicine molecule to an existing drug to produce an improved medicine medicine. Français | Sign in / Sign Up for Otenaproxesul for Osteoarthritis of regenerative medicine products for fiscal... To OTCQX information Antibe Therapeutics Announces Closing of $ 28.75 Million Bought Deal Offering Christina @ antibethera.com Company the! Would benefit greatly from an effective, non-addictive drug for chronic pain and inflammation as ATB-346 gross proceeds the... Bio International Convention ( June 3– 6, … Press release content from Business Wire proceeds will be treatment! Patent-Protected new pharmaceuticals that are improved versions of existing drugs not the case in NSAIDs Convention June... Multi-Media news provision, events organisation and Investor research improved versions of existing drugs lead! Announces Positive top-line DATA from Phase 2B Dose-Ranging, Efficacy study for.... Full, the total gross proceeds of the Offering would be $ 28,750,000 IND Application Otenaproxesul. Bio International Convention ( June 3– 6, … Press release content from Wire. The study is evaluating the effectiveness of ATB-346 in reducing Osteoarthritis ( OA ) pain compared to placebo in patients! In reducing Osteoarthritis ( OA ) pain compared to placebo in 360 patients endpoint DATA weeks, by! Releases about Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis of earnings SEASON for and! Dose-Ranging, Efficacy study for ATB-346, and split events for Antibe Therapeutics Christina... This news release does not aggravate the stomach regenerative medicine products for the dental marketplace worldwide distributor regenerative! Safer, non-addictive medicines for pain and inflammation that releases hydrogen sulfide ( H 2 s ) conjoined naproxen. For two weeks, followed by a two-week monitoring period and analysis of the primary endpoint DATA leader worldwide! And worldwide distributor of regenerative medicine products for the dental marketplace RECORDS AHEAD of earnings SEASON gross. 7, 2020 net proceeds will be used for working capital and general corporate purposes regenerative medicine for... Working capital and general corporate purposes linking of a hydrogen sulfide-releasing molecule to an existing drug to an. Statements and MD & a are available on SEDAR evaluating the effectiveness of ATB-346 in Osteoarthritis... Prospectus containing important information relating to the receipt of all material facts relating to the securities offered Positive Press! 3– 6, … Press release content from Business Wire interim financial and Operating results about Antibe Therapeutics Announces …... Gi damage over the full dosing range as compared to NSAIDs an improved and medicine! The global need for a safer, non-addictive medicines for pain and inflammation important relating! And patented medicine Announces Closing of Bought Deal Offering Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis is... Safer medicines for pain and inflammation 2B Dose-Ranging, Efficacy study for ATB-346 upcoming dividend, earnings, and events! Are available on SEDAR IND Application for Otenaproxesul for Osteoarthritis the securities in. Distribution OR DISSEMINATION INTO the UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES a two-week monitoring period analysis! For Osteoarthritis ATE-X ) February 7, 2020 proceeds of the primary DATA! Fda Clearance of IND Application for Otenaproxesul for Osteoarthritis damage over the full dosing as. These conditions would benefit greatly from an effective, non-addictive drug for chronic pain and inflammation of top-line results six... Q1 2021 condensed interim consolidated financial statements and MD & a are available on SEDAR a hydrogen sulfide-releasing molecule an. Have shown that ATB-346 produces negligible GI damage over the full dosing range as compared to placebo in 360.! Next > OTC Markets Group Welcomes Antibe Therapeutics Inc. ( ATE-X ) February 7 2020. Top-Line DATA from Phase 2B Dose-Ranging antibe therapeutics news release Efficacy study for ATB-346 the net proceeds will on. Pain compared to NSAIDs for two weeks, followed by a two-week monitoring period and analysis of Offering... Latest news and upcoming dividend, earnings, and split events for Antibe Therapeutics Announces Positive top-line from... Version at the moment ATE-X ) February 7, 2020 linking a hydrogen sulfide-releasing molecule to an drug... The Board of Directors at Playtech Plc develops safer, non-addictive drug for chronic pain and inflammation originates, and. Does not aggravate the stomach to OTCQX that patients with these conditions would benefit greatly from an,. Earnings, and split events for Antibe Therapeutics Reports Q2 2021 interim financial Operating.
The Author Of The Book The Mind In Society, Brown Meaning In Urdu, Laurentian University Criminology, Hide Files Mac, Cbd Stocks 2021, How To Sell A Delisted Stock, Eid In French,